Oxygen Biotherapeutics, Inc. (OXBO) Engages PPD to Execute Remainder of Phase IIb Clinical Trial to Evaluate the Safety and Tolerability of Oxycyte® in Severe Traumatic Brain Injury
11/20/2012 8:54:05 AM
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), announced today that it is partnering with Pharmaceutical Product Development, LLC (PPD), a global contract research organization, to resume and complete OBI’s STOP-TBI (Safety and Tolerability of Oxycyte in Patients with Severe non-Penetrating Traumatic Brain Injury) Phase II-b clinical trial. “The development of Oxycyte® as a potential breakthrough therapy for severe traumatic brain injury remains the top priority of this company, and for the past 12 months we have remained committed to resuming enrollment in our clinical trials. Engaging a qualified CRO is a critical step in getting trial sites back up and running and open for enrollment by year-end,” said Michael Jebsen, President and Chief Financial Officer of OBI.